According to the state council, the office of the state council recently issued a number of opinions on sound drug price development mechanisms, aimed at improving market-led drug price formation mechanisms, supporting the high-quality development of the pharmaceutical industry and guaranteeing access to quality and affordable medicines for the population. On 15 april, the press office of the state council held a routine policy briefing on the situation。
The deputy director-general of the national health insurance agency, shi zhihai, presented the idea of an effective market and a combination of government, proposing a series of reforms from a holistic, holistic and cross-cutting perspective that would lead to the rational formation of prices, regulation of price order and coordinated governance of medicines, with a view to promoting stable markets, maintaining a good price order and ensuring the safety of the population。
Precision initiatives in support of development
In order to encourage development, the national drug authority has continuously improved the efficiency of its reviews, reducing the average time taken for clinical trials by 71 per cent compared to the “1355” period and 42 per cent for priority reviews. As of february this year, the medical insurance fund had cumulatively spent $50. 4 billion on the negotiation of medicines during the agreement period, generating $740 billion in sales, benefiting 1. 17 billion people every time. The opinion proposes precise support measures at every stage of the approved listing: at the initial stage of the drug, explore the application of a self-assessment of the clinical value and innovation of the enterprise, and support the high level of pricing and relative stability appropriate for high input and high risk at the early stages of the listing; at the stage of entry into health care, optimize the rules for cataloguing and negotiating prices for the sale of medicines in non-specified medical institutions, which are not subject to the standard of payment of health insurance; and at the stage of participation in the collection of medicines, make it clear that the collection does not involve “innovation, integration, non-innovation”。
Further development of mechanisms for the pricing of medicines
The national health insurance agency, together with the authorities concerned, will adhere to the principles of “stable clinical, quality assurance, anti-infiltration, anti-fault-proofing” and further develop mechanisms for the collection of medicines. Specific initiatives include optimizing the collection rules for different types of drugs, such as chemicals, biopharmaceuticals, medium medicines and tablets, improving the match with clinical choices and leading firms to rational competition. The second is to enhance the implementation of the selected results of collection and to guide medical institutions to prioritize the use of the selected products, while using other non-selective products to avoid “one-size-fits-all”. The third is to strengthen guidance on local harvesting and encourage the adoption of the “one-provincial, national-level” inter-provincial clustering model to raise the level of collection standardization。
The "medicine box" of the people's people
According to ho yajun, director-general of the department of product industry of the ministry of industry and information technology, the total number of approved medicines in our country is approximately 160,000, which can produce a full range of pharmaceutical products that basically meet the daily needs of the population. My country is studying about one third of the world, with authorized overseas transactions totalling over $130 billion in 2025. The industrial base continues to be consolidated, the advantages of integration with formulations have expanded, and the development and industrialization of chinese medicines has been a breakthrough. The continued improvement of the national pharmaceutical reserve system has effectively eased the supply of more than 130 essential clinical drugs. The national commission for health and health has indicated that the shortage of medicines in our country has been greatly reduced in recent years。
With regard to the quality of medicines, the national agency for medicines and medicines maintains a “two-cover” check-up and a “two-cover” check-up of selected varieties at the selected enterprises, which have covered 490 varieties and over 800 selected enterprises in all 11 national collections. In recent years, the overall pass rate for drug tests has remained at over 99 per cent. Market regulators will also vigorously combat prices and monopolistic offences in the field of medicines, safeguarding market order and the legitimate rights and interests of the population in the use of medicines。
